Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00497666|
Recruitment Status : Unknown
Verified July 2007 by Assaf-Harofeh Medical Center.
Recruitment status was: Not yet recruiting
First Posted : July 9, 2007
Last Update Posted : July 9, 2007
Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy.
We decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.
|Condition or disease||Intervention/treatment|
|Diabetes Diabetic Nephropathy Renal Protection||Drug: Rosiglitasone (retrospective observation)|
Show Detailed Description
|Study Type :||Observational|
|Observational Model:||Case Control|
|Official Title:||Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study|
|Study Start Date :||August 2007|
|Estimated Study Completion Date :||December 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00497666
|Contact: Leonid S Feldman||+972-8-9779383 ext firstname.lastname@example.org|
|Clalit Health Cervices, Central District||Not yet recruiting|
|Zerifin,, Israel, 70300|
|Contact: Leonid S Feldman +972-8-9779383 ext 9383 email@example.com|
|Sub-Investigator: Shlomo Vinker, MD|
|Principal Investigator:||Leonid S Feldman||Nephrology Division, Assaf Harofeh Medical Center, Zerifin,|
|Principal Investigator:||Leonid S Feldman||Assaf-Harofeh Medical Center|